Medical considerations before international travel

New England Journal of Medicine

Volumn 375, Issue 3, 2016, Pages 247-260

  Freedman, David O ^a   Chen, Lin H ^b,c   Kozarsky, Phyllis E ^d  

^a University of Alabama at Birmingham   (United States)

^b MOUNT AUBURN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; HEPATITIS A VACCINE; MEASLES MUMPS RUBELLA VACCINE; YELLOW FEVER VACCINE;

ALTITUDE DISEASE; CONSULTATION; GEOGRAPHIC DISTRIBUTION; HEALTH EDUCATION; HUMAN; INFECTION RISK; MALARIA CONTROL; MEDICAL INFORMATION; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; THROMBOSIS; TRAVEL; TRAVELLER DIARRHEA; VACCINATION; ARBOVIRUS INFECTIONS; DIARRHEA; EMPORIATRICS; ENDEMIC DISEASES; INTERNATIONAL COOPERATION; JET LAG SYNDROME; MALARIA; RABIES; STANDARDS; TUBERCULOSIS, PULMONARY;

ARBOVIRUS INFECTIONS; DIARRHEA; ENDEMIC DISEASES; HUMANS; INTERNATIONALITY; JET LAG SYNDROME; MALARIA; RABIES; TRAVEL; TRAVEL MEDICINE; TUBERCULOSIS, PULMONARY; VACCINATION;

EID: 84979675826     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1508815     Document Type: Review

References (77)

1. Leder K, Torresi J, Libman MD, et al. GeoSentinel surveillance of illness in returned travelers, 2007-2011. Ann Intern Med 2013;158:456-68.
2. Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med 2006;354:119-30.
3. Mendelson M, Han PV, Vincent P, et al. Regional variation in travel-related illness acquired in Africa, March 1997-May 2011. Emerg Infect Dis 2014;20:532-41.
4. Monsel G, Caumes E. What's new in travel-associated dermatology? J Travel Med 2015;22:221-4.
5. Jensenius M, Han PV, Schlagenhauf P, et al. Acute and potentially life-threatening tropical diseases in western travelers - a GeoSentinel multicenter study, 1996-2011. Am J Trop Med Hyg 2013;88:397-404.
6. LaRocque RC, Rao SR, Tsibris A, et al. Pre-travel health advice-seeking behavior among US international travelers departing from Boston Logan International Airport. J Travel Med 2010;17:387-91.
7. Schlagenhauf P, Weld L, Goorhuis A, et al. Travel-associated infection presenting in Europe (2008-12): an analysis of EuroTravNet longitudinal, surveillance data, and evaluation of the effect of the pre-travel consultation. Lancet Infect Dis 2015;15:55-64.
8. Leder K, Tong S, Weld L, et al. Illness in travelers visiting friends and relatives: a review of the GeoSentinel Surveillance Network. Clin Infect Dis 2006;43:1185-93.
9. LaRocque RC, Deshpande BR, Rao SR, et al. Pre-travel health care of immigrants returning home to visit friends and relatives. Am J Trop Med Hyg 2013;88:376-80.
10. LaRocque RC, Rao SR, Lee J, et al. Global TravEpiNet: a national consortium of clinics providing care to international travelers - analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011. Clin Infect Dis 2012;54:455-62.
11. Kotton CN, Freedman DO. Immunocompromised travelers. In: Centers for Disease Control and Prevention. CDC health information for international travel 2016. New York: Oxford University Press, 2016:622-33.
12. Visser LG. The immunosuppressed traveler. Infect Dis Clin North Am 2012;26:609-24.
13. Hochberg NS, Barnett ED, Chen LH, et al. International travel by persons with medical comorbidities: understanding risks and providing advice. Mayo Clin Proc 2013;88:1231-40.
14. Keller-Stanislawski B, Englund JA, Kang G, et al. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine 2014;32:7057-64.
15. Lupi E, Hatz C, Schlagenhauf P. The efficacy of repellents against Aedes, Anopheles, Culex and Ixodes spp. - a literature review. Travel Med Infect Dis 2013;11:374-411.
16. Pages F, Dautel H, Duvallet G, Kahl O, de Gentile L, Boulanger N. Tick repellents for human use: prevention of tick bites and tick-borne diseases. Vector Borne Zoonotic Dis 2014;14:85-93.
17. Coltart CE, Chew A, Storrar N, et al. Schistosomiasis presenting in travellers: a 15 year observational study at the Hospital for Tropical Diseases, London. Trans R Soc Trop Med Hyg 2015;109:214-20.
18. Leshem E, Segal G, Barnea A, et al. Travel-related leptospirosis in Israel: a nationwide study. Am J Trop Med Hyg 2010;82:459-63.
19. Jackson SS, Chen WH. Evidence for CVD 103-HgR as an effective single-dose oral cholera vaccine. Future Microbiol 2015;10:1271-81.
20. Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-7):1-23.
21. Theeten H, Van Herck K, Van Der Meeren O, Crasta P, Van Damme P, Hens N. Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions. Vaccine 2015;33:5723-7.
22. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006;55(RR-16):1-33.
23. FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011. Vaccine 2013;31:584-90.
24. Van Damme P, Leroux-Roels G, Crasta P, Messier M, Jacquet JM, Van Herck K. Antibody persistence and immune memory in adults, 15 years after a three-dose schedule of a combined hepatitis A and B vaccine. J Med Virol 2012;84:11-7.
25. Grohskopf LA, Sokolow LZ, Olsen SJ, Broder KR, Karron RA. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 influenza season. MMWR Morb Mortal Wkly Rep 2015;64:818-25.
26. Fischer M, Lindsey N, Staples JE, Hills S. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010;59(RR-1):1-27.
27. Recommendations for use of a booster dose of inactivated vero cell culture-derived Japanese encephalitis vaccine: advisory committee on immunization practices, 2011. MMWR Morb Mortal Wkly Rep 2011;60:661-3.
28. Jelinek T, Burchard GD, Dieckmann S, et al. Short-term immunogenicity and safety of an accelerated pre-exposure prophylaxis regimen with Japanese encephalitis vaccine in combination with a rabies vaccine: a Phase III, multicenter, observer-blind study. J Travel Med 2015;22:225-31.
29. European Medicines Agency. Summary of product characteristics: IXIARO suspension for injection, Japanese encephalitis vaccine (inactivated, adsorbed) (http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000963/WC500037287.pdf).
30. Paulke-Korinek M, Kollaritsch H, Kundi M, Zwazl I, Seidl-Friedrich C, Jelinek T. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis. Vaccine 2015;33:3600-4.
31. Rabe IB, Miller ER, Fischer M, Hills SL. Adverse events following vaccination with an inactivated, Vero cell culture-derived Japanese encephalitis vaccine in the United States, 2009-2012. Vaccine 2015;33:708-12.
32. McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013;62(RR-04):1-34.
33. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013;62(RR-2):1-28.
34. Baxter R, Baine Y, Kolhe D, Baccarini CI, Miller JM, Van der Wielen M. Five-year antibody persistence and booster response to a single dose of meningococcal A, C, W and Y tetanus toxoid conjugate vaccine in adolescents and young adults: an open, randomized trial. Pediatr Infect Dis J 2015;34:1236-43.
35. Wallace GS, Seward JF, Pallansch MA. Interim CDC guidance for polio vaccination for travel to and from countries affected by wild poliovirus. MMWR Morb Mortal Wkly Rep 2014;63:591-4.
36. Manning SE, Rupprecht CE, Fishbein D, et al. Human rabies prevention - United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep 2008;57(RR-3):1-28.
37. Wieten RW, Leenstra T, van Thiel PP, et al. Rabies vaccinations: are abbreviated intradermal schedules the future? Clin Infect Dis 2013;56:414-9.
38. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep 2011;60:13-5.
39. Jackson BR, Iqbal S, Mahon B. Updated recommendations for the use of typhoid vaccine - Advisory Committee on Immunization Practices, United States, 2015. MMWR Morb Mortal Wkly Rep 2015;64:305-8.
40. Gershman MD, Staples JE. Yellow fever. In: Centers for Disease Control and Prevention. CDC health information for international travel 2016. New York: Oxford University Press, 2016:346-60.
41. Vaccines and vaccination against yellow fever: WHO position paper - June 2013. Wkly Epidemiol Rec 2013;88:269-83.
42. Staples JE, Bocchini JA Jr, Rubin L, Fischer M. Yellow fever vaccine booster doses: recommendations of the Advisory Committee on Immunization Practices, 2015. MMWR Morb Mortal Wkly Rep 2015;64:647-50.
43. Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 2010;85:117-28.
44. Vaccines against tick-borne encephalitis: WHO position paper. Wkly Epidemiol Rec 2011;86:241-56.
45. Jost M, Luzi D, Metzler S, Miran B, Mutsch M. Measles associated with international travel in the region of the Americas, Australia and Europe, 2001-2013: a systematic review. Travel Med Infect Dis 2015;13:10-8.
46. Chiappini E, Stival A, Galli L, de Martino M. Pertussis re-emergence in the post-vaccination era. BMC Infect Dis 2013;13:151.
47. Steffen R, Behrens RH, Hill DR, Greenaway C, Leder K. Vaccine-preventable travel health risks: what is the evidence - what are the gaps? J Travel Med 2015;22:1-12.
48. Azziz Baumgartner E, Dao CN, Nasreen S, et al. Seasonality, timing, and climate drivers of influenza activity worldwide. J Infect Dis 2012;206:838-46.
49. Nielsen US, Petersen E, Larsen CS. Hepatitis B immunization coverage and risk behaviour among Danish travellers: are immunization strategies based on single journey itineraries rational? J Infect 2009;59:353-9.
50. Leder K, Chen LH, Wilson ME. Aggregate travel vs. single trip assessment: arguments for cumulative risk analysis. Vaccine 2012;30:2600-4.
51. Mogasale V, Maskery B, Ochiai RL, et al. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with riskfactor adjustment. Lancet Glob Health 2014;2(10):e570-80.
52. Mahon BE, Newton AE, Mintz ED. Effectiveness of typhoid vaccination in US travelers. Vaccine 2014;32:3577-9.
53. Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine 2008;26:6077-82.
54. Collaborative Group for Studies on Yellow Fever Vaccines. Duration of postvaccination immunity against yellow fever in adults. Vaccine 2014;32:4977-84.
55. Jentes ES, Blanton JD, Johnson KJ, et al. The global availability of rabies immune globulin and rabies vaccine in clinics providing indirect care to travelers. J Travel Med 2014;21:62-6.
56. Jentes ES, Blanton JD, Johnson KJ, et al. The global availability of rabies immune globulin and rabies vaccine in clinics providing direct care to travelers. J Travel Med 2013;20:148-58.
57. Gautret P, Parola P. Rabies vaccination for international travelers. Vaccine 2012;30:126-33.
58. Wilder-Smith A, Leong WY, Lopez LF, et al. Potential for international spread of wild poliovirus via travelers. BMC Med 2015;13:133.
59. Freedman DO. Malaria prevention in short-term travelers. N Engl J Med 2008;359:603-12.
60. Schlagenhauf P, Hatz C, Behrens R, et al. Mefloquine at the crossroads? Implications for malaria chemoprophylaxis in Europe. Travel Med Infect Dis 2015;13:192-6.
61. Schlagenhauf P, Petersen E. Standby emergency treatment of malaria in travelers: experience to date and new developments. Expert Rev Anti Infect Ther 2012;10:537-46.
62. Chen LH, Wilson ME, Schlagenhauf P. Prevention of malaria in long-term travelers. JAMA 2006;296:2234-44.
63. Schwartz E, Weld LH, Wilder-Smith A, et al. Seasonality, annual trends, and characteristics of dengue among ill returned travelers, 1997-2006. Emerging Infect Dis 2008;14:1081-8.
64. Vannice KS, Roehrig JT, Hombach J. Next generation dengue vaccines: a review of the preclinical development pipeline. Vaccine 2015;33:7091-9.
65. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med 2015;372:1231-9.
66. Musso D, Gubler DJ. Zika virus. Clin Microbiol Rev 2016;29:487-524.
67. Delord M, Socolovschi C, Parola P. Rickettsioses and Q fever in travelers (2004-2013). Travel Med Infect Dis 2014;12:443-58.
68. Steffen R, Hill DR, DuPont HL. Traveler's diarrhea: a clinical review. JAMA 2015;313:71-80.
69. Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Aliment Pharmacol Ther 2011;34:1269-81.
70. Connor BA, Riddle MS. Post-infectious sequelae of travelers' diarrhea. J Travel Med 2013;20:303-12.
71. Kantele A, Lääveri T, Mero S, et al. Anti microbials increase travelers' risk of colonization by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Clin Infect Dis 2015;60:837-46.
72. Ruppé E, Armand-Lefèvre L, Estellat C, et al. High rate of acquisition but short duration of carriage of multidrug-resistant Enterobacteriaceae after travel to the tropics. Clin Infect Dis 2015;61:593-600.
73. Hassing RJ, Alsma J, Arcilla MS, van Genderen PJ, Stricker BH, Verbon A. International travel and acquisition of multidrug-resistant Enterobacteriaceae: a systematic review. Euro Surveill 2015;20(47).
74. Kantele A, Mero S, Kirveskari J, Lääveri T. Increased risk for ESBL-producing bacteria from co-administration of loperamide and antimicrobial drugs for travelers' diarrhea. Emerg Infect Dis 2016;22:117-20.
75. Luks AM, McIntosh SE, Grissom CK, et al. Wilderness Medical Society practice guidelines for the prevention and treatment of acute altitude illness: 2014 update. Wilderness Environ Med 2014;25:Suppl:S4-14.
76. Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:2Suppl:e195S-226S.
77. Lapostolle F, Surget V, Borron SW, et al. Severe pulmonary embolism associated with air travel. N Engl J Med 2001;345:779-83.